Compound News and Research

RSS

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

Researchers package drug-loaded 'nanodisks' into vault nanoparticles for therapeutic drug delivery

There's no question, drugs work in treating disease. But can they work better, and safer?

22 Apr 2011

Researchers discover new compound to fight against shingles

Researchers at the University of Georgia and Yale University have discovered a compound with the potential to be more effective than existing agents in treating the very painful blisters known as shingles-a condition that affects up to 30 percent of Americans, mostly elderly, and for which no specific treatment exists.

22 Apr 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement granting Hanmi Pharmaceuticals exclusive rights to their lead compound, KX01, for all oncology indications in selected Asian Territories.

21 Apr 2011

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results.

21 Apr 2011

Military personnel with TBI should receive adequate protein and calories immediately after trauma

To help alleviate the effects of severe traumatic brain injury (TBI), the U.S. Department of Defense should ensure that all military personnel with this type of injury receive adequate protein and calories immediately after the trauma and through the first two weeks of treatment, says a new report from the Institute of Medicine.

21 Apr 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Anavex: First-in-human dosing cmmenced in ANAVEX 2-73 clinical trial for Alzheimer’s

Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease. “We are pleased that the first volunteers have been dosed with the study drug, according to the study protocol, and no adverse events have been recorded post dosing to date," said Dr. Ozkan Yalkinoglou, Medical Director of ABX-CRO.

20 Apr 2011

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative mitochondrial therapies, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, during multiple scientific sessions of the Experimental Biology 2011 meeting.

20 Apr 2011

Aduro raises $19.25 million through Series B equity financing

Aduro BioTech, a clinical-stage immunotherapy company, announced today that it has completed its Series B equity financing from a combination of current investors and Morningside Ventures, bringing the total capital secured in this round to $19.25 million. In addition, Ms. Stephanie O'Brien, who represents Morningside, has joined Aduro's Board of Directors.

20 Apr 2011

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANAT®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.

20 Apr 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Combination therapy restores skilled use of limb in rodent model

After the acute treatment window closes, the only effective treatment for stroke is physical/occupational therapy. Now scientists from Children's Hospital Boston report a two-pronged molecular therapy that leads to significant recovery of skilled motor function in a rat model of stroke.

20 Apr 2011

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

On the heels of Centers for Disease Control announcement earlier today that an ongoing study of the use of Gilead's top selling AIDS treatment, Truvada, as a possible form of pre-exposure prophylaxis for HIV prevention in women is being abruptly halted because the, "…trial could not demonstrate efficacy," the AIDS Healthcare Foundation renewed its call on Gilead Sciences to slow its fast track pursuit of its application for FDA approval of use of its AIDS drug as a possible form of HIV prevention.

20 Apr 2011

OSU biophysicist leverages computer cluster to develop drug to block small protein molecule IL-6

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.

20 Apr 2011

Cord blood units treated with signaling molecule show favorable safety profile in long-term animal studies

An innovative experimental treatment for boosting the effectiveness of stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies, report scientists from Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Children's Hospital Boston.

20 Apr 2011

Ohio State biophysicist disrupts cellular messages through fragment-based drug design

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.

19 Apr 2011

Cumberland acquires Vanderbilt's ifetroban rights

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.

19 Apr 2011

Researchers identify TrkB antagonist with anxiolytic, antidepressant activity

An estimated 19 million Americans suffer from depression, and though the symptoms might be recognizable, the brain chemistry that underlies them is incompletely understood.

19 Apr 2011

Compound News and Research

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

Researchers package drug-loaded 'nanodisks' into vault nanoparticles for therapeutic drug delivery

Researchers discover new compound to fight against shingles

Repligen anticipates 30% increase in total revenues for 2011

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Military personnel with TBI should receive adequate protein and calories immediately after trauma

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Anavex: First-in-human dosing cmmenced in ANAVEX 2-73 clinical trial for Alzheimer’s

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Aduro raises $19.25 million through Series B equity financing

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Combination therapy restores skilled use of limb in rodent model

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

OSU biophysicist leverages computer cluster to develop drug to block small protein molecule IL-6

Cord blood units treated with signaling molecule show favorable safety profile in long-term animal studies

Ohio State biophysicist disrupts cellular messages through fragment-based drug design

Cumberland acquires Vanderbilt's ifetroban rights

Researchers identify TrkB antagonist with anxiolytic, antidepressant activity

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News